^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Title:

The combination of trametinib and ganitumab is effective in RAS-mutated PAX-fusion negative rhabdomyosarcoma models

Published date:
11/02/2022
Excerpt:
Treatment with trametinib and ganitumab resulted in synergistic cellular growth inhibition in all cell lines tested and inhibition of tumor growth in four out of six models of RAS-mutant RMS....We demonstrate that combined trametinib and ganitumab is effective in a genomically diverse panel of RAS-mutated FN RMS preclinical models.
DOI:
https://doi.org/10.1158/1078-0432.CCR-22-1646